Generic placeholder image

Current Drug Safety

Author(s): Sarah Cherri*, Diana Malaeb*, Lamis Shouman, Iqbal Fahs, Rabih Hallit, Souheil Hallit, Bassem Malaeb and Pascale Salameh

DOI: 10.2174/1574886317666220620153115

DownloadDownload PDF Flyer Cite As
Assessment of Antimicrobial Utilization among Cancer Patients with Febrile Neutropenia at the Lebanese Hospitals

Page: [496 - 503] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Febrile neutropenia is a prevalent oncologic complication. Initiating rapid treatment with empirical antimicrobials in febrile neutropenia patients reduces mortality due to infections.

Objectives: The study aims to evaluate antimicrobial utilization among FN patients in Lebanon in terms of drug choice, dose, and duration of the treatment. This is a retrospective, multicenter, observational study conducted at three different Lebanese university hospitals (in which the Infectious Diseases Society of America (IDSA) guidelines are adopted), between February 2014 and May 2017.

Methods: Adult cancer patients aged 18 years and older with febrile neutropenia were included in the study. Using the IDSA guidelines as a reference, patients were assessed whether they received the antimicrobial regimen inconsistent with the IDSA reference or not. Statistical analysis was performed using the Statistical Package for the Social Science software (SPSS version 22.0). The adherence to guidelines for the indication and doses of antibiotics and anti-fungal in patients with febrile neutropenia.

Results: A total of 124 patients with a mean age of 54.43 ± 17.86 years were enrolled in the study. Leukemia (29.7%) was the most prevalent cancer and the most common infection was sepsis (20.2%). Combination antibiotic lactams are the most prescribed antibiotics (86.8%). Only 94 (86.23%) patients were given the antibiotic therapy appropriate for choice, dose, and duration. Empirical antifungal therapy was initiated in 63.7% of the patients and fluconazole was the most used antifungal (36.3%). In contrast to antibiotics, the majority of antifungal choices were not selected according to the recommendations and they were considered inappropriate for doses and the required treatment duration as proposed by (IDSA). Fifty-eight percent of patients received antivirals, even though it is not recommended as empirical treatment.

Conclusion: In conclusion, this study reveals a non-consistent antimicrobial utilization practice at the involved sites concerning FN treatment. Inappropriateness was encountered in drug selection, dose, and duration of treatment with antifungals and antivirals.

Keywords: Antibiotic, antifungal, antiviral, febrile neutropenia, evaluation, hospital.

Graphical Abstract

[1]
Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38(4): 1045-53.
[http://dx.doi.org/10.1097/CCM.0b013e3181cc4824] [PMID: 20048677]
[2]
Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 (Suppl. 4): S240-5.
[http://dx.doi.org/10.1086/427329] [PMID: 15768329]
[3]
Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39 (Suppl. 1): S32-7.
[http://dx.doi.org/10.1086/383050] [PMID: 15250018]
[4]
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the infectious diseases society of america. Clin Infect Dis 2011; 52(4): 427-31.
[http://dx.doi.org/10.1093/cid/ciq147] [PMID: 21205990]
[5]
Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36(9): 1103-10.
[http://dx.doi.org/10.1086/374339] [PMID: 12715303]
[6]
Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 2010; 6(3): 149-52.
[http://dx.doi.org/10.1200/JOP.091092] [PMID: 20808559]
[7]
Santolaya ME, Álvarez AM, Bidart T, Morales J, González C. Antimicrobial therapy in cancer patients and hematopoietic stem cell transplantation receptors. Rev Chilena Infectol 2019; 36(2): 167-78.
[http://dx.doi.org/10.4067/S0716-10182019000200167] [PMID: 31344153]
[8]
Calik S, Ari A, Bilgir O, et al. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. Saudi Med J 2018; 39(9): 878-85.
[http://dx.doi.org/10.15537/smj.2018.9.22824] [PMID: 30251730]
[9]
Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43(4): 447-59.
[http://dx.doi.org/10.1086/505393] [PMID: 16838234]
[10]
Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IG, Prentice A. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005; 11 (Suppl. 5): 17-23.
[http://dx.doi.org/10.1111/j.1469-0691.2005.01239.x] [PMID: 16138815]
[11]
Cherif H, Björkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36(8): 593-600.
[http://dx.doi.org/10.1080/00365540410017590] [PMID: 15370671]
[12]
Klaassen RJ, Goodman TR, Pham B, Doyle JJ. “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18(5): 1012-9.
[http://dx.doi.org/10.1200/JCO.2000.18.5.1012] [PMID: 10694551]
[13]
Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2013; 2016(10): CD003992.
[http://dx.doi.org/10.1002/14651858.CD003992.pub3] [PMID: 24105485]
[14]
Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44(2): 159-77.
[http://dx.doi.org/10.1086/510393] [PMID: 17173212]
[15]
Görük M, Dal M, Dal T, et al. Evaluation of febrile neutropenic patients hospitalized in a hematology clinic. Asian Pac J Trop Biomed 2015; 5(12): 1051-4.
[http://dx.doi.org/10.1016/j.apjtb.2015.09.014]
[16]
Okera M, Chan S, Dernede U, et al. A prospective study of chemotherapy-induced febrile neutropenia in the South West London cancer network. Interpretation of study results in light of NCAG/NCEPOD findings. Br J Cancer 2011; 104(3): 407-12.
[http://dx.doi.org/10.1038/sj.bjc.6606059] [PMID: 21179036]
[17]
Alp S, Akova M. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis 2013; 1(1): 37-43.
[http://dx.doi.org/10.1177/2049936113475610] [PMID: 25165543]
[18]
Hamzeh F, Kanj SS, Uwaydah M. Febrile neutropenia in cancer patients in a tertiary care medical center in Lebanon: Microbial spectrum and outcome. J Med Liban 2000; 48(3): 136-42.
[PMID: 11268566]
[19]
Kanj SS, Adel N, Araj GF. The continued prevalence of Gram-negative infections in febrile neutropenic patients in Lebanon. Comparison with studies from the Middle East. BMJ 2001; 8: 6-13.
[20]
Kanafani ZA, Dakdouki GK, El-Chammas KI, Eid S, Araj GF, Kanj SS. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: A view of the past decade. Int J Infect Dis 2007; 11(5): 450-3.
[http://dx.doi.org/10.1016/j.ijid.2006.12.008] [PMID: 17337226]
[21]
Sakr R, Massoud M, Greige W, et al. Outcome of neutropenic fever in hospitalized cancer patients during a one-year follow-up: A single center experience. Clin Lymphoma Myeloma Leuk 2017; 17: S386.
[http://dx.doi.org/10.1016/j.clml.2017.07.236]
[22]
Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34(6): 730-51.
[http://dx.doi.org/10.1086/339215] [PMID: 11850858]
[23]
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106(10): 2258-66.
[http://dx.doi.org/10.1002/cncr.21847] [PMID: 16575919]
[24]
Roongpoovapatr P, Suankratay C. Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2010; 93(7): 776-83.
[PMID: 20649055]
[25]
United States Cancer Statistics. 2017. Available from: https://www.cdc.gov/uscs/toptencancers.aspx (Accessed on June 6, 2022).
[26]
Berger NA. Young adult cancer: Influence of the obesity pandemic. Obesity 2018; 26(4): 641-50.
[http://dx.doi.org/10.1002/oby.22137] [PMID: 29570247]
[27]
Stone TW, McPherson M, Gail Darlington L. Obesity and cancer: Existing and new hypotheses for a causal connection. EBioMedicine 2018; 30: 14-28.
[http://dx.doi.org/10.1016/j.ebiom.2018.02.022] [PMID: 29526577]
[28]
De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013; 2013: 11.
[29]
Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist 2010; 15(10): 1083-101.
[http://dx.doi.org/10.1634/theoncologist.2010-0206] [PMID: 20930095]
[30]
Lima SS, França MS, Godoi CC, et al. Neutropenic patients and their infectious complications at a University Hospital. Rev Bras Hematol Hemoter 2013; 35(1): 18-22.
[http://dx.doi.org/10.5581/1516-8484.20130009] [PMID: 23580879]
[31]
Billote KP, Mendoza MY, Baylon HG. Infections in febrile neutropenia and possible prognostic factors associated with mortality. Philipp J Microbiol Infect Dis 1997; 26(2): 55-9.